BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:crizanlizumab-tmca (Adakveo) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of crizanlizumab-tmca (Adakveo)\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05469828-10308@assetmemo.bio
DTSTAMP:20261121T010020Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 1/2 readout est. (NCT05469828)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 1/2\, Sickle Cell Disease.
 \nStudy: Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Pa
 tients With Sickle Cell Anemia\nEstimated primary completion: 1 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/crizanlizumab-tmca-a
 dakveo#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05469828
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909618-10308@assetmemo.bio
DTSTAMP:20261121T010020Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 2 readout est. (NCT05909618)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 2.\nStudy: Crizanlizumab A
 lone or in Combination With Nivolumab for Glioblastoma and Melanoma With B
 rain Metastases\nEstimated primary completion: 30 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05909618
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439082-10308@assetmemo.bio
DTSTAMP:20261121T010020Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 3 readout est. (NCT06439082)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 3\, Sickle Cell Disease.\n
 Study: A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 
 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease P
 atients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)\nEstimated
  primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06439082
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04657822-10308@assetmemo.bio
DTSTAMP:20261121T010020Z
DTSTART;VALUE=DATE:20310610
DTEND;VALUE=DATE:20310611
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 4 readout est. (NCT04657822)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 4\, Sickle Cell Disease.\n
 Study: Rollover Study for Patients With Sickle Cell Disease Who Have Compl
 eted a Prior Novartis-Sponsored Crizanlizumab Study\nEstimated primary com
 pletion: 10 June 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/crizanlizumab-tmca-adakveo#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04657822
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
